The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
A Novel Class of Anticancer Compounds Targets the Actin Cytoskeleton in Tumor Cells
Abstract
The actin cytoskeleton is a potentially vulnerable property of cancer cells, yet chemotherapeutic targeting attempts have been hampered by unacceptable toxicity. In this study, we have shown that it is possible to disrupt specific actin filament populations by targeting isoforms of tropomyosin, a core component of actin filaments, that are selectively upregulated in cancers. A novel class of anti-tropomyosin compounds has been developed that preferentially disrupts the actin cytoskeleton of tumor cells, impairing both tumor cell motility and viability. Our lead compound, TR100, is effective in vitro and in vivo in reducing tumor cell growth in neuroblastoma and melanoma models. Importantly, TR100 shows no adverse impact on cardiac structure and function, which is the major side effect of current anti-actin drugs. This proof-of-principle study shows that it is possible to target specific actin filament populations fundamental to tumor cell viability based on their tropomyosin isoform composition. This improvement in specificity provides a pathway to the development of a novel class of anti-actin compounds for the potential treatment of a wide variety of cancers. Cancer Res; 73(16); 5169–82. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States
Hoek, K. S., Eichhoff, O. M., Schlegel, N. C., Döbbeling, U., Kobert, N., Schaerer, L., Hemmi, S., & Dummer, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2491 · Cited by 743
Puthalakath, H., Villunger, A., O'Reilly, L. A., Beaumont, J. G., Coultas, L., Cheney, R. E., Huang, D. C. S., & Strasser, A. (2001) · Science · doi:10.1126/science.1062257 · Cited by 656
Cited by
Movers and shakers: cell cytoskeleton in cancer metastasis
Fife, C. M., McCarroll, J. A., & Kavallaris, M. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12704 · Cited by 551
Migrastatics—Anti-metastatic and Anti-invasion Drugs: Promises and Challenges
Gandalovičová, A., Rosel, D., Fernandes, M., Veselý, P., Heneberg, P., Čermák, V., Petruželka, L., Kumar, S., Sanz-Moreno, V., & Brábek, J. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.04.008 · Cited by 351
Datta, A., Deng, S., Gopal, V., Yap, K. C.-H., Halim, C. E., Lye, M. L., Ong, M. S., Tan, T. Z., Sethi, G., Hooi, S. C., et al. (2021) · Cancers · doi:10.3390/cancers13081882 · Cited by 184
Metadata
- Authors
- Stehn, J. R., Haass, N. K., Bonello, T., Desouza, M., Kottyan, G., Treutlein, H., Zeng, J., Nascimento, P. R. B. B., Sequeira, V. B., Butler, T. L., Allanson, M., Fath, T., Hill, T. A., McCluskey, A., Schevzov, G., Palmer, S. J., Hardeman, E. C., Winlaw, D., Reeve, V. E., Dixon, I., Weninger, W., Cripe, T. P., & Gunning, P. W.
- Venue
- Cancer Research
- Published
- 2013-08-13
- Volume
- 73
- Issue
- 16
- Pages
- 5169-5182
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2144600779
- Cited by
- 169
- References
- 3
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Novel Class of Anticancer Compounds Targets the Actin Cytoskeleton in Tumor Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-4501
- The paper
- Stehn, J. R., Haass, N. K., Bonello, T., Desouza, M., Kottyan, G., Treutlein, H., Zeng, J., Nascimento, P. R. B. B., Sequeira, V. B., Butler, T. L., Allanson, M., Fath, T., Hill, T. A., McCluskey, A., Schevzov, G., Palmer, S. J., Hardeman, E. C., Winlaw, D., Reeve, V. E., . . . Gunning, P. W. (2013). A Novel Class of Anticancer Compounds Targets the Actin Cytoskeleton in Tumor Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-4501
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.